Kadmon D - Search Results

1

Therapeutic targets for metastatic prostate cancer.

Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC. Timme TL, et al. Among authors: kadmon d. Curr Drug Targets. 2003 Apr;4(3):251-61. doi: 10.2174/1389450033491127. Curr Drug Targets. 2003. PMID: 12643475 Review.

2

Transforming growth factor beta 1 as a biomarker for prostate cancer.

Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Thompson TC, et al. Among authors: kadmon d. J Cell Biochem Suppl. 1992;16H:54-61. doi: 10.1002/jcb.240501212. J Cell Biochem Suppl. 1992. PMID: 1289674 Review.

3

Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas.

Thompson TC, Egawa S, Kadmon D, Miller GJ, Timme TL, Scardino PT, Park SH. Thompson TC, et al. Among authors: kadmon d. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):79-85. doi: 10.1016/0960-0760(92)90190-t. J Steroid Biochem Mol Biol. 1992. PMID: 1525069

4

Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma.

Egawa S, Kadmon D, Miller GJ, Scardino PT, Thompson TC. Egawa S, et al. Among authors: kadmon d. Mol Carcinog. 1992;5(1):52-61. doi: 10.1002/mc.2940050110. Mol Carcinog. 1992. PMID: 1543541

5

Experimental oncogene induced prostate cancer.

Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH. Thompson TC, et al. Among authors: kadmon d. Cancer Surv. 1991;11:55-71. Cancer Surv. 1991. PMID: 1726789

6

BCG and the treatment of superficial bladder cancer.

Moss JT, Kadmon D. Moss JT, et al. Among authors: kadmon d. DICP. 1991 Dec;25(12):1355-67. doi: 10.1177/106002809102501215. DICP. 1991. PMID: 1815434 Review.

7

Elevated plasma chromogranin-A concentrations in prostatic carcinoma.

Kadmon D, Thompson TC, Lynch GR, Scardino PT. Kadmon D, et al. J Urol. 1991 Aug;146(2):358-61. doi: 10.1016/s0022-5347(17)37793-5. J Urol. 1991. PMID: 1856931

8

Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression.

Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC. Merz VW, et al. Among authors: kadmon d. Mol Endocrinol. 1991 Apr;5(4):503-13. doi: 10.1210/mend-5-4-503. Mol Endocrinol. 1991. PMID: 1922083

9

Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer.

Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Thompson TC, et al. Among authors: kadmon d. Oncogene. 1995 Mar 2;10(5):869-79. Oncogene. 1995. PMID: 7534899

10

Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth.

Timme TL, Truong LD, Slawin KM, Kadmon D, Park SH, Thompson TC. Timme TL, et al. Among authors: kadmon d. Microsc Res Tech. 1995 Mar 1;30(4):333-41. doi: 10.1002/jemt.1070300408. Microsc Res Tech. 1995. PMID: 7541677 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters